Table 2 Number and percentage of adverse drug reactions reported in the 161 patients exposed to thiazolidinediones in the French PharmacoVigilance database from 2002 to 2006.
System Organ Classification terms | Number of patients (%) |
|---|---|
Body as a whole - general disorders 1810 | 69 (42.8) |
Metabolic and nutritional disorders 0800 | 64 (39.7) |
Cardiovascular disorders, general 1010; Myo-, endo-, pericardial & valve disorders 1020; Heart rate and rhythm disorders 1030 | 42 (26.1) |
Skin and appendages disorders 0100 | 35 (21.7) |
Central & peripheral nervous system disorders 0410 | 33 (20.5) |
Red blood cell disorders 1210; White cell and reticulo-endotelial system disorders 1220; Platelet, bleeding & clotting disorders 1230 | 26 (16.1) |
Gastro-intestinal system disorders 0600 | 21 (13.0) |
Liver and biliary system disorders 0700 | 15 (9.3) |
Psychiatric disorders 0500 | 13 (8.1) |
Respiratory system disorders 1100 | 11 (6.8) |
Urinary system disorders 1300 | 7 (4.3) |
Vascular (extra-cardiac) disorders 1040 | 6 (3.7) |
Vision disorders 0431; Hearing and vestibular disorders 0432; Special senses other, disorders 0433 | 5 (3.1) |
Endocrine disorders 0900 | 4 (2.5) |
Immune system | 3 (1.9) |
Muscular-skeletal system disorders 0200 | 2 (1.2) |
Fetal disorders 1500 | 2 (1.2) |
Total number of adverse drug reactions | 358 |